Androgen receptor gene and hormonal therapy failure of prostate cancer

American Journal of Pathology

Volumn 152, Issue 1, 1998, Pages 1-9

  Koivisto, Pasi ^a   Kolmer, Meelis ^b   Visakorpi, Tapio ^a   Kallioniemi, Olli P ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; MESSENGER RNA; MONOCLONAL ANTIBODY; NILUTAMIDE; SEX HORMONE; STEROID 5ALPHA REDUCTASE; TRANSCRIPTION FACTOR;

CANCER HORMONE THERAPY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HORMONE DEPENDENCE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR RECURRENCE;

GENE THERAPY; HORMONES; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TREATMENT FAILURE;

EID: 0031975628     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Huggins C, Hodges CV: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297
2. Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C: Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993, 16:475-492
3. Wilding G: Endocrine control of prostate cancer. Cancer Surv 1995, 23:43-62
4. Kallioniemi O-P, Visakorpi T: Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res 1996, 68:225-255
5. Gottlieb B, Trifiro M, Lumbroso R, Pinsky L: The androgen receptor gene mutations database. Nucleic Acid Res 1997, 25:158-162
6. Greyhack J, Keeler T, Kozlowski J: Carcinoma of the prostate: hormonal therapy. Cancer 1987, 60:589-601
7. Westin P, Stattin P, Damber J-E, Bergh A: Castration therapy induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995, 146:1368-1375
8. Klein L: Prostatic carcinoma. N Engl J Med 1979, 300:824
9. Gittes RF: Carcinoma of the prostate. N Engl J Med 1991, 324:236-245
10. Beato M, Herrlich P, Schütz G: Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83:851-857
11. Hakimi JM, Rondinelli RH, Schoenberg MB, Barrack ER: Androgen receptor gene structure and function in prostate cancer. World J Urol 1996, 14:329-337
12. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992, 89:6319-6323
13. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H: Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993, 7:1541-1550
14. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993, 46:759-765
15. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994, 54:2861-2864
16. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, van der Kwast TH: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994, 144:735-746
17. 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994, 198:74-80
18. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332:1393-1398
19. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P: In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nature Genet 1995, 9:401-406
20. Koivisto P, Kononen J, Palmberg C, Hyytinen E, Tammela T, Trapman J, Isola J, Visakorpi T, Kallioniemi O-P: Androgen receptor gene amplification: a possible molecular mechanism for failure of androgen deprivation therapy in prostate cancer. Cancer Res 1997, 57:314-319
21. Tilley WD, Buchanan G, Hickey TE, Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996, 2:277-285
22. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P: Mutated human androgen receptor gene detected in a prostatic cancer patients is also activated by estradiol. J Clin Endocrinol Metab 1995, 80:3494-3500
23. Evans BAJ, Harper ME, Daniels CE, Watts CE, Matenhelia S, Green J, Griffiths K: Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 1996, 28:162-171
24. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer relation to antiandrogen withdrawal syndrome. Prostate 1996, 29:153-158
25. Koivisto P, Hyytinen E, Palmberg C, Visakorpi T, Isola J, Kallioniemi O-P: FISH analysis of genetic changes underlying recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 1995, 147:1608-1614
26. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH: Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol 1997, 31:1-6
27. Isaacs WB: Molecular genetics of prostate cancer. Cancer Surv 1995, 25:357-379
28. Lee C: Cellular interactions in prostate cancer. Br J Urol 1997, 79(suppl):21-27
29. Brinkmann AO, Jenster G, Kuiper GGJM, Ris C, van der Korput JAGM, Degenhart HJ, Trifiro MA, Pinsky L, Romalo G, Schweikert HU, Veldscholte J, Mulder E, Trapman J: The human androgen receptor: structure/function relationship in normal and pathological situations. J Steroid Biochem Mol Biol 1992, 41:361-368
30. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P: The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839
31. Chang C, Kokontis J, Liao S: Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324-326
32. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ: Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci USA 1989, 86:327-331
33. Adler AJ, Danielsen M, Robins DM: Androgen-specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Natl Acad Sci USA 1991, 89:11660-11663
34. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQuenn SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonalds BS: Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993, 7:23-26
35. Bohmann D, Bos TJ, Admon A, Nishimura T, Vogt PK, Tjian R: Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1987, 238:1386-1392
36. Boss TJ, Bohmann D, Tsuchie H, Tjian R, Vogt PK: v-jun encodes a nuclear protein with enhancer binding properties of AP-1. Cell 1988, 52:705-712
37. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM: c-fos is required for malignant progression of skin tumors. Cell 1995, 82:721-732
38. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA: Mutual transcriptional interference between RelA and androgen receptor. J Biol Chem 1996, 271:24151-24156
39. Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L: c-Jun can mediate androgen receptor-induced transactivation. J Biol Chem 1996, 271:24583-24589
40. 70, for the androgen receptor n human prostate cells. Proc Natl Acad Sci USA 1996, 93:5517-5521
41. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968
42. Kallio PJ, Poukka H, Moilanen A, Janne OA, Palvimo JJ: Androgen receptor-mediated transcriptional regulation in the absence of direct interaction with a specific DNA element. Mol Endocrinol 1995, 9:1017-1028
43. Blanquet V, Wang J, Chenivesse X, Henglein B, Garreau F, Brechot C, Turleau C: Assignment of a human cyclin A gene to 4q26-q27. Genomics 1990, 8:595-597
44. Hunter T, Pines J: Cyclins and cancer. Cell 1991, 66:1071-1074
45. Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A: Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 1996, 56:4159-4163
46. Xiong Y, Connelly T, Futcher B, Beach D: Human D-type cyclin. Cell 1991, 65:691-699
47. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994, 91:709-713
48. Inaba T, Matsushime H, Valentine M, Roussel MF, Sherr CJ, Look AT: Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics 1992, 13:565-574
49. Lew DJ, Dulic V, Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (cln) function in yeast. Cell 1991, 66:1197-1206
50. Li H, Lahti JM, Valentine M, Saito M, Reed SI, Look AT, Kidd VJ: Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics 1996, 32:253-259
51. Meyerson M, Enders GH, Wu C-L, Su L-K, Gorka C, Nelson C, Harlow E, Tsai L-H: A family of human cdc2-related protein kinases. EMBO J 1992, 11:2909-2917
52. Demetrick DJ, Zhang H, Beach DH: Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes. Cytogenet Cell Genet 1994, 66:72-74
53. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet 1996, 12: 97-99
54. Fujita J, Yoshida O, Yuasa Y, Rhim JS, Hatanaka M, Aaronson SA: Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours. Nature 1984, 309:464-466
55. Yokota J, Tsunetsugu-Yokota Y, Battifora H, Le Fevre C, Cline MJ: Alterations of myc, myb, and ras(Ha) proto-oncogenes in cancers are frequent and show clinical correlation. Science 1986, 231:261-265
56. Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986, 314:133-137
57. Bushman EC, Nayak RN, Bushman W: Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue. J Urol 1995, 153:233-237
58. Brissenden JE, Ullrich A, Francke U: Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature 1984, 310:781-784
59. Muir GH, Butta A, Shearer RJ, Fisher C, Dearnaley DP, Flanders KC, Sporn MB, Colletta AA: Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 1994, 69: 130-134
60. Sherwood ER, Lee C: Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995, 13:290-296
61. Story MT: Regulation of prostate growth by fibroblast growth factors. World J Urol 1995, 13:297-305
62. Culig Z, Hobisch A, Cronaur MV, Radmayr C, Hittmair A, Zhang J, Thurnher M, Bartsch G, Klocker H: Regulation of prostatic growth and function by peptide growth factors. Prostate 1996, 28:392-405
63. Ittman M, Mansukhani A: Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997, 157:351-356
64. Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990, 50:3748-3753
65. Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal. J Urol 1993, 149:607-609
66. Scher HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993, 11:566-572
67. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH, Kantoff PW: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 1997, 94:3320-3323
68. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi O-P: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995, 55:142-147
69. Kellens RE: Gene Amplification in Mammalian Cells: A Comprehensive Guide. New York, Marcel Dekker, 1993
70. Göker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan C, Berman E, Bertino JR: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoplastic leukemia and is correlated with p53 gene mutations. Blood 1995, 86:677-684
71. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 1991, 48:189-193
72. Sadi MV, Walsh PC, Barrack ER: Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991, 67:3057-3064
73. Koivisto P: Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification. Prostate Cancer Prostatic Dis 1997, 1:21-25
74. Belanger A, Brochu M, Cliche J: Levels of plasma steroid glucuronides in intact and castrated men with prostate cancer. J Clin Endocrinol Metab 1986, 62:812-815
75. Labrie F, Dupont A, Belanger A, St Arnaud R, Gigeure M, Lacourciere Y, Emond J, Monfette G: Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986, 7:67-74
76. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995, 346:265-269
77. Nazareth LV, Weigel NL: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem 1996, 271:19900-19907